CN106008635A - 含半乳糖苷结构三氮唑类去甲斑蝥素衍生物及其制备方法与应用 - Google Patents
含半乳糖苷结构三氮唑类去甲斑蝥素衍生物及其制备方法与应用 Download PDFInfo
- Publication number
- CN106008635A CN106008635A CN201610398107.5A CN201610398107A CN106008635A CN 106008635 A CN106008635 A CN 106008635A CN 201610398107 A CN201610398107 A CN 201610398107A CN 106008635 A CN106008635 A CN 106008635A
- Authority
- CN
- China
- Prior art keywords
- galactoside
- methanol
- room temperature
- reaction
- norcantharidin derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Triazole norcantharidin derivative Chemical class 0.000 title claims abstract description 19
- 150000008195 galaktosides Chemical group 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims abstract description 18
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 7
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 5
- 229930182830 galactose Natural products 0.000 claims abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- HXBYBCASAVUYKF-YTQLPXDHSA-N (4r,5s,6s,7r)-4,5,6,7,8-pentahydroxyoctane-2,3-dione Chemical compound CC(=O)C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO HXBYBCASAVUYKF-YTQLPXDHSA-N 0.000 claims description 9
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000005457 ice water Substances 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 229940095758 cantharidin Drugs 0.000 claims description 6
- 229930008397 cantharidin Natural products 0.000 claims description 6
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 150000003949 imides Chemical class 0.000 claims description 5
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 239000003729 cation exchange resin Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 230000003292 diminished effect Effects 0.000 claims description 3
- 239000003456 ion exchange resin Substances 0.000 claims description 3
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 2
- 238000005698 Diels-Alder reaction Methods 0.000 claims description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000006356 dehydrogenation reaction Methods 0.000 claims description 2
- 230000008676 import Effects 0.000 claims description 2
- 229940071125 manganese acetate Drugs 0.000 claims description 2
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 claims description 2
- 238000010189 synthetic method Methods 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims 1
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical group C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 abstract description 14
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 abstract 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 7
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 150000003852 triazoles Chemical class 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 150000000177 1,2,3-triazoles Chemical class 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- JAABVEXCGCXWRR-UHFFFAOYSA-N norcantharidin Chemical compound C1CC2C3C(=O)OC(=O)C3C1O2 JAABVEXCGCXWRR-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- DDFGTVSLZJLQEV-UHFFFAOYSA-N [C](C1CCCCC1)C1CCCCC1 Chemical compound [C](C1CCCCC1)C1CCCCC1 DDFGTVSLZJLQEV-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610398107.5A CN106008635B (zh) | 2016-06-06 | 2016-06-06 | 含半乳糖苷结构三氮唑类去甲斑蝥素衍生物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610398107.5A CN106008635B (zh) | 2016-06-06 | 2016-06-06 | 含半乳糖苷结构三氮唑类去甲斑蝥素衍生物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106008635A true CN106008635A (zh) | 2016-10-12 |
CN106008635B CN106008635B (zh) | 2018-10-23 |
Family
ID=57090627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610398107.5A Active CN106008635B (zh) | 2016-06-06 | 2016-06-06 | 含半乳糖苷结构三氮唑类去甲斑蝥素衍生物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106008635B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112110969A (zh) * | 2020-05-29 | 2020-12-22 | 绍兴文理学院 | 3-硝基-1-甲酸乙酯-7-氮杂吲哚的三氮唑糖苷衍生物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101717411A (zh) * | 2009-11-19 | 2010-06-02 | 绍兴文理学院 | 去甲基斑蝥素衍生物磷酸二钠盐及其合成方法与用途 |
CN101812066A (zh) * | 2010-03-04 | 2010-08-25 | 绍兴文理学院 | 吡唑并n-取代去甲去氢斑蝥素酰亚胺衍生物及其合成方法、活性测试方法与应用 |
CN102276673A (zh) * | 2011-06-21 | 2011-12-14 | 中国科学院成都生物研究所 | 一种2-脱氧-β-D-吡喃葡萄糖基三唑类化合物的制备方法 |
CN104817605A (zh) * | 2015-04-14 | 2015-08-05 | 湖北工程学院 | 2-(1’,2’,3’-三氮唑-4’-氧苄基)-1,3,4,6-o-乙酰基-d-葡萄糖及其制备方法和应用 |
-
2016
- 2016-06-06 CN CN201610398107.5A patent/CN106008635B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101717411A (zh) * | 2009-11-19 | 2010-06-02 | 绍兴文理学院 | 去甲基斑蝥素衍生物磷酸二钠盐及其合成方法与用途 |
CN101812066A (zh) * | 2010-03-04 | 2010-08-25 | 绍兴文理学院 | 吡唑并n-取代去甲去氢斑蝥素酰亚胺衍生物及其合成方法、活性测试方法与应用 |
CN102276673A (zh) * | 2011-06-21 | 2011-12-14 | 中国科学院成都生物研究所 | 一种2-脱氧-β-D-吡喃葡萄糖基三唑类化合物的制备方法 |
CN104817605A (zh) * | 2015-04-14 | 2015-08-05 | 湖北工程学院 | 2-(1’,2’,3’-三氮唑-4’-氧苄基)-1,3,4,6-o-乙酰基-d-葡萄糖及其制备方法和应用 |
Non-Patent Citations (6)
Title |
---|
LIPING DENG,等: "Disodium Phosphate of Norcantharidin Analogues: Design, Synthesis and their Anticancer Evaluation", 《LETTERS IN DRUG DESIGN & DISCOVERY》 * |
LIPING DENG,等: "Novel 1, 2, 3-Triazole-Linked Norcantharidin Analogues: Synthesis and Evaluation of Growth Inhibition in a Panel of Selected Tumor-Cell Lines", 《LETTERS IN DRUG DESIGN & DISCOVERY》 * |
PERUMAL RAJAKUMAR,等: "Synthesis and In-vitro anti-inflammatory activity of novel glycodendrimers with benzene 1,3,5 carboxamide core and triazole as branching unit", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
RAM JANAM SINGH: "1, 2, 3-TRIAZOLE DERIVATIVES AS POSSIBLE ANTIINFLAMMATORY AGENTS", 《RASAYAN J.CHEM.》 * |
赵岩,等: "去甲斑蝥素主动肝靶向性药物设计研究进展", 《环球中医药》 * |
高建德,等: "《物理药剂学及应用》", 31 May 2014 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112110969A (zh) * | 2020-05-29 | 2020-12-22 | 绍兴文理学院 | 3-硝基-1-甲酸乙酯-7-氮杂吲哚的三氮唑糖苷衍生物及其制备方法和应用 |
CN112110969B (zh) * | 2020-05-29 | 2022-07-12 | 绍兴文理学院 | 3-硝基-1-甲酸乙酯-7-氮杂吲哚的三氮唑糖苷衍生物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106008635B (zh) | 2018-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103896954B (zh) | 一种吡唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN103554123B (zh) | 含色酮结构吡唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN103554135B (zh) | 一种含色酮结构异噁唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN106397445A (zh) | 含有色酮结构的吡唑类n‐对溴苯基马来酰亚胺衍生物及其制备方法与应用 | |
CN105924486A (zh) | 含麦芽糖苷结构三氮唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN103554122B (zh) | 一种含色酮结构吡唑类去甲斑蝥素衍生物及其制备方法与应用 | |
Sandeli et al. | Silver (I)-N-heterocyclic carbene complexes: Synthesis and characterization, biological evaluation of Anti-Cholinesterase, anti-alpha-amylase, anti-lipase, and antibacterial activities, and molecular docking study | |
Zhao et al. | Synthesis and potential antineoplastic activity of dehydroabietylamine imidazole derivatives | |
CN105906678A (zh) | 氟取代含葡萄糖苷结构三氮唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN106008635A (zh) | 含半乳糖苷结构三氮唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN107286220A (zh) | 1,2,4‑三氮唑偶联的二氢杨梅素衍生物及其制备方法和应用 | |
CN106083967A (zh) | 含阿拉伯糖苷结构三氮唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN106083966A (zh) | 氟取代含半乳糖苷结构三氮唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN106967146B (zh) | 齐墩果酸四唑衍生物及其制备方法和用途 | |
CN106220642A (zh) | 一种l‑亮氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN106008634A (zh) | 氟取代含阿拉伯糖苷结构三氮唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN106083968A (zh) | 含葡萄糖苷结构三氮唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN106083965A (zh) | 含乳糖苷结构三氮唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN103554134B (zh) | 含色酮结构异噁唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN106188081B (zh) | 一种d-缬氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN103739617B (zh) | 异噁唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN115109083B (zh) | Pyridostatin类化合物及其制备方法、应用、药物组合物 | |
CN101108791B (zh) | 取代的苯丙烯类衍生物及其制备方法和用途 | |
CN110105364A (zh) | 含吡唑结构N-对氯苯基取代马来酰亚胺α-松油烯环加成衍生物及其制备方法和应用 | |
CN105906634A (zh) | 3-(6-溴-4-氧-4H-色酮)-1-苯基-5-对甲氧基苯基-1,6a-二氢吡咯啉[3,4-c]吡唑-4,6(3aH,5H)-二酮及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191204 Address after: Room 314-1, dantaihu building (Wuluo Science Park), No.9, Taihu East Road, Wuzhong District, Suzhou, Jiangsu Province Patentee after: Suzhou ruipengcheng Technology Co.,Ltd. Address before: 312000, No. 508 West Ring Road, Yuecheng District, Zhejiang, Shaoxing Patentee before: Shaoxing University |
|
TR01 | Transfer of patent right |
Effective date of registration: 20240815 Address after: No.11 Yonglong Industrial Street, Jun'an Town, Shunde District, Foshan City, Guangdong Province Patentee after: Foshan Shunde jieying Industrial Co.,Ltd. Country or region after: China Address before: Room 314-1, dantaihu building (Wuluo Science Park), No.9, Taihu East Road, Wuzhong District, Suzhou City, Jiangsu Province, 215100 Patentee before: Suzhou ruipengcheng Technology Co.,Ltd. Country or region before: China |